Item 9.01 Financial Statements and Exhibits.






(a)     Financial Statements of Businesses Acquired.

The audited financial statements of Oncoceutics as of and for the year ended December 31, 2020, together with the notes thereto and the auditor's report thereon, are attached hereto as Exhibit 99.1 and are incorporated herein by reference. The consent of CohnReznick LLP, the independent auditor of Oncoceutics, is attached hereto as Exhibit 23.1 to this Current Report on Form 8-K.





(b)     Pro Forma Financial Information

The unaudited pro forma consolidated combined statement of operations for the Company and Oncoceutics for the year ended December 31, 2020 that gives effect to the acquisition of Oncoceutics is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The unaudited pro forma consolidated combined balance sheet for the Company and Oncoceutics as of December 31, 2020 is not presented as the Merger is already reflected in the consolidated balance sheet for the Company as of March 31, 2021. The unaudited pro forma consolidated combined statement of operations for the Company and Oncoceutics for the three months ended March 31, 2021 is not presented as there is no material difference between the pro forma amounts and the actual results.





(d)    Exhibits



Exhibit No.   Description
  23.1          Consent of CohnReznick LLP, independent auditor.
  99.1          Audited financial statements of Oncoceutics as of and for the year
              ended December 31, 2020, together with the notes thereto and the
              auditor's report thereon.
  99.2          Unaudited pro forma consolidated combined statement of operations
              for the Company and Oncoceutics for the year ended December 31,
              2020.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses